AGWCA
ROIV icon

Annis Gardner Whiting Capital Advisors’s Roivant Sciences ROIV Stock Holding History

Annis Gardner Whiting Capital Advisors’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-49
Closed -$1.36K – 1054
2026
Q1 		$1.36K Buy
49
+11
+29% +$283 ﹤0.01% 1103
2025
Q4 		$825 Buy
+38
New +$750 ﹤0.01% 1070

Other funds holding ROIV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Annis Gardner Whiting Capital Advisors's ROIV Position: Q2 2026 in Review

Annis Gardner Whiting Capital Advisors sold out of Roivant Sciences (ROIV) in Q2 2026, closing a stake of 49 shares — an estimated $1.36K sold.

Annis Gardner Whiting Capital Advisors first reported a position in ROIV in Q4 2025 and held it in 2 quarters. The position peaked at $1.36K in Q1 2026. 500 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

  • Annis Gardner Whiting Capital Advisors reported no remaining Roivant Sciences position as of Q2 2026 after selling out during the quarter.
  • Annis Gardner Whiting Capital Advisors sold 49 Roivant Sciences shares in Q2 2026, an estimated $1.36K.
  • Annis Gardner Whiting Capital Advisors first reported a position in Roivant Sciences in Q4 2025 and held it in 2 quarters.
  • Annis Gardner Whiting Capital Advisors's Roivant Sciences position peaked at $1.36K in Q1 2026.
  • 500 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on Annis Gardner Whiting Capital Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.